Literature DB >> 18222164

Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement.

Ian Chopra1, Christopher Schofield, Martin Everett, Alex O'Neill, Keith Miller, Mark Wilcox, Jean-Marie Frère, Mike Dawson, Lloyd Czaplewski, Uros Urleb, Patrice Courvalin.   

Abstract

This consensus statement presents the conclusions of a group of academic and industrial experts who met in London in September, 2006, to consider the issues associated with the treatment of hospital infections caused by Gram-negative bacteria. The group discussed the severe clinical problems arising from the emergence of antibiotic resistance in these bacteria and the lack of new antibacterial agents to challenge the threat. The discovery of new drugs active against hospital-acquired Gram-negative bacteria is essential to prevent a future medical and social catastrophe. An important strategy to promote drug discovery will be the development of focused cooperations between academic institutions and small pharmaceutical companies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18222164     DOI: 10.1016/S1473-3099(08)70018-5

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  58 in total

Review 1.  Structure-based discovery of antibacterial drugs.

Authors:  Katie J Simmons; Ian Chopra; Colin W G Fishwick
Journal:  Nat Rev Microbiol       Date:  2010-07       Impact factor: 60.633

2.  Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid.

Authors:  Georgina Cox; Gary S Thompson; Huw T Jenkins; Frank Peske; Andreas Savelsbergh; Marina V Rodnina; Wolfgang Wintermeyer; Steve W Homans; Thomas A Edwards; Alexander J O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-20       Impact factor: 11.205

3.  Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms.

Authors:  Rinki Kapoor; Mayken W Wadman; Michelle T Dohm; Ann M Czyzewski; Alfred M Spormann; Annelise E Barron
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

4.  A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.

Authors:  Martti Vaara; Osmo Siikanen; Juha Apajalahti; John Fox; Niels Frimodt-Møller; Hui He; Anima Poudyal; Jian Li; Roger L Nation; Timo Vaara
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

5.  Virtual screening for potential inhibitors of homology modeled Leptospira interrogans MurD ligase.

Authors:  Amineni Umamaheswari; Dibyabhaba Pradhan; Marisetty Hemanthkumar
Journal:  J Chem Biol       Date:  2010-05-13

6.  New Peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging.

Authors:  Jean-Marie Pagès; Slavka Kascàkovà; Laure Maigre; Anas Allam; Mickael Alimi; Jacqueline Chevalier; Erwan Galardon; Matthieu Réfrégiers; Isabelle Artaud
Journal:  ACS Med Chem Lett       Date:  2013-05-07       Impact factor: 4.345

7.  In silico identification of common putative drug targets in Leptospira interrogans.

Authors:  U Amineni; D Pradhan; H Marisetty
Journal:  J Chem Biol       Date:  2010-05-14

8.  Using Chemical Probes to Assess the Feasibility of Targeting SecA for Developing Antimicrobial Agents against Gram-Negative Bacteria.

Authors:  Jinshan Jin; Ying-Hsin Hsieh; Jianmei Cui; Krishna Damera; Chaofeng Dai; Arpana S Chaudhary; Hao Zhang; Hsiuchin Yang; Nannan Cao; Chun Jiang; Martti Vaara; Binghe Wang; Phang C Tai
Journal:  ChemMedChem       Date:  2016-10-18       Impact factor: 3.466

9.  Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead.

Authors:  Dianqing Sun; Julian G Hurdle; Robin Lee; Richard Lee; Mark Cushman; John M Pezzuto
Journal:  ChemMedChem       Date:  2012-07-30       Impact factor: 3.466

10.  New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors.

Authors:  Laurent Mamelli; Sylvain Petit; Jacqueline Chevalier; Carmela Giglione; Aurélie Lieutaud; Thierry Meinnel; Isabelle Artaud; Jean-Marie Pagès
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.